NASDAQ:ENTO Entero Therapeutics (ENTO) Stock Price, News & Analysis $4.25 -0.30 (-6.59%) As of 10/14/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Entero Therapeutics Stock (NASDAQ:ENTO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Entero Therapeutics alerts:Sign Up Key Stats Today's Range$4.25▼$4.9850-Day Range$2.74▼$4.9752-Week Range$0.32▼$5.84Volume62,259 shsAverage Volume2.80 million shsMarket Capitalization$6.75 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Entero Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing orally delivered therapies for gastrointestinal diseases and disorders. The company’s research and development efforts are aimed at addressing conditions with limited treatment options, including diseases involving impaired digestion and intestinal inflammation. Entero’s lead product candidate is adrulipase, an orally administered recombinant enzyme being developed as a potential treatment for exocrine pancreatic insufficiency, a condition in which the pancreas does not produce enough digestive enzymes. The company has evaluated adrulipase for potential use in conditions such as cystic fibrosis and chronic pancreatitis. The company was formerly known as First Wave BioPharma, Inc. and adopted the Entero Therapeutics name as part of its strategic focus on gastrointestinal therapeutics. Entero is headquartered in Boca Raton, Florida, and its programs are being advanced through clinical development and partnerships intended to support the potential commercialization of treatments for gastrointestinal conditions.AI Generated. May Contain Errors. Read More Receive ENTO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Entero Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ENTO Stock News HeadlinesEntero Therapeutics (NASDAQ:ENTO) Shares Climb 16.5% - Time to Buy?October 10, 2026 | americanbankingnews.comGridAI Technologies Faces Default on Revolving Loan AgreementApril 24, 2026 | tipranks.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.October 15 at 1:00 AM | InvestorPlace (Ad)Entero Therapeutics Inc.December 4, 2025 | wsj.comNASDAQ: ENTO’s Grid AI Strikes Texas Hyperscale Deal as its $50M Industrial Software Platform Enters the AI RaceNovember 19, 2025 | msn.comEntero's Grid AI Announces Major U.S. Expansion and Incoming Leadership to Accelerate AI Infrastructure StrategyNovember 19, 2025 | finance.yahoo.comEntero Therapeutics Delays Q3 10-Q FilingNovember 17, 2025 | tipranks.comEntero’s Grid AI Prepares for Major U.S. Expansion with New Leadership Appointments to Accelerate AI Infrastructure StrategyNovember 16, 2025 | usatoday.comSee More Headlines ENTO Stock Analysis - Frequently Asked Questions How have ENTO shares performed this year? Entero Therapeutics' stock was trading at $4.66 at the start of the year. Since then, ENTO shares have decreased by 8.8% and is now trading at $4.25. How were Entero Therapeutics' earnings last quarter? Entero Therapeutics, Inc. (NASDAQ:ENTO) posted its quarterly earnings results on Thursday, August, 14th. The company reported ($0.42) earnings per share for the quarter. When did Entero Therapeutics' stock split? Entero Therapeutics shares reverse split on Monday, August 18th 2025.A 1-3 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, August 17th 2025. An investor that had 100 shares of stock prior to the reverse split would have 33 shares after the split. When did Entero Therapeutics IPO? Entero Therapeutics (ENTO) raised $5 million in an initial public offering on Friday, September 16th 2016. The company issued 960,000 shares at $5.50 per share. How do I buy shares of Entero Therapeutics? Shares of ENTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/14/2025Today10/15/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorTechnology Industry Software Sub-IndustryApplication Software Current SymbolNASDAQ:ENTO Previous SymbolNASDAQ:ENTO CIK1604191 Webwww.enterothera.com Phone561-589-7020FaxN/AEmployees9Year FoundedN/AProfitability EPS (Trailing Twelve Months)($1.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$18.06 million Net MarginsN/A Pretax MarginN/A Return on Equity-461.02% Return on Assets-14.72% Debt Debt-to-Equity RatioN/A Current Ratio2.62 Quick Ratio2.62 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($2.45) per share Price / Book-1.73Miscellaneous Outstanding Shares1,588,000Free Float3,337,000Market Cap$6.75 million OptionableN/A Beta1.19 The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:ENTO) was last updated on 10/14/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entero Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
